Transgene and Sofimac Partners Invest in Antibody Start-Up
Transgene SA, a biopharmaceutical company that develops targeted immunotherapy products to treat cancer and chronic infectious diseases, said on Tuesday that it has participated in a first round of financing in ElsaLys Biotech, an antibody start-up. No financial terms were disclosed. Another investor is Sofimac Partners, a France-based investment firm, which along with Transgene, is ElsaLys Biotech's largest shareholder; although each with a minority holding.
21 May 2013•4 mins read
